Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 115

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 115
---
 Launch Products* which totaled JPY 2,201.9 billion (JPY +375.9 billion and +20.6% AER, +14.7% CER), partially offset by lower sales of VYVANSE in the U. S. and AZILVA in Japan, which were impacted by generic competition following loss of exclusivities.

* Takeda’s Growth and Launch Products for the fiscal year ended March 31, 2025

GI: ENTYVIO, EOHILIA

Rare Diseases: TAKHZYRO, LIVTENCITY, ADZYNMA

PDT: Immunoglobulin products including GAMMAGARD LIQUID/KIOVIG, HYQVIA, and CUVITRU,

Albumin products including HUMAN ALBUMIN and FLEXBUMIN

Oncology: 　　　　 ALUNBRIG, FRUZAQLA

Vaccines: QDENGA

Core Operating Profit

Core Operating Profit for the fiscal year ended March 31, 2025 was JPY 1,162.6 billion (JPY +107.8 billion and +10.2% AER,+4.9% CER). The components of Core Operating Profit are as below:

                                                                 Billion JPY or percentage                                                                                               
                                                                 For the fiscal year ended                                                 AER                                      CER  
                                                                 March 31,                                                                                                               
                                                                 2024                                          2025                        Amount of Change      % Change      % Change  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Core revenue                                                   ¥                                4,263.8      ¥              4,579.8      ¥                          7.4           2.8  
  Core cost of sales                                                                            (1,426.3)                   (1,581.8)      (155.5)                   10.9           6.6  
  Core selling, general and administrative (SG& A) expenses                                     (1,053.0)                   (1,105.0)      (52.1)                     4.9           0.7  
  Core research and development (R& D) expenses                  (729.6)                                       (730.4)                     (0.7)                      0.1         (4.4)  
  Core operating profit                                          ¥                                1,054.9      ¥